Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
CD19/CD22 CAR-T (Essen Biotech) in Follicular Lymphoma: NCT06213636 Clinical Landscape Report 2026
16 October 2026
NCT06213636 clinical landscape for Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lurbinectedin in Locally Advanced Soft Tissue Sarcoma: NCT06217536 Clinical Landscape Report 2026
16 October 2026
NCT06217536 clinical landscape for Locally Advanced Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
MVR-T3011 in Melanoma: NCT06214156 Clinical Landscape Report 2026
16 October 2026
NCT06214156 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tenalisib in Triple Negative Breast Cancer: CTRI/2024/01/061635 Clinical Landscape Report 2026
16 October 2026
CTRI/2024/01/061635 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Trilaciclib Dihydrochloride in Osteosarcoma: NCT06217003 Clinical Landscape Report 2026
16 October 2026
NCT06217003 clinical landscape for Osteosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vusolimogene oderparepvec-wtpg in Uveal Melanoma: NCT06216938 Clinical Landscape Report 2026
16 October 2026
NCT06216938 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NT-112 in Adenocarcinoma of large intestine: NCT06218914 Clinical Landscape Report 2026
16 October 2026
NCT06218914 clinical landscape for Adenocarcinoma of large intestine: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Iohexol in Triple Negative Breast Cancer: NCT06220214 Clinical Landscape Report 2026
16 October 2026
NCT06220214 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bicalutamide in Renal Cell Carcinoma: NCT06222593 Clinical Landscape Report 2026
16 October 2026
NCT06222593 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GLB-002 in Follicular Lymphoma: NCT06219356 Clinical Landscape Report 2026
16 October 2026
NCT06219356 clinical landscape for Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in T-cell/histiocyte rich large B-cell lymphoma: NCT06220032 Clinical Landscape Report 2026
16 October 2026
NCT06220032 clinical landscape for T-cell/histiocyte rich large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Sotiburafusp alfa in Renal Cell Carcinoma: NCT06222125 Clinical Landscape Report 2026
16 October 2026
NCT06222125 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.